Independent biostatistics and capital analysis for clinical-stage biotechnology.

Helix Data Analytics reads primary trial data the way an analyst reads a balance sheet — and reads capital structure the way a scientist reads a protocol.

Capabilities

CFA Charterholder · MBA, Business Economics

Independent · Ponte Vedra, Florida

The firm

Two disciplines, one desk.

Most people who can read a survival curve cannot read a capital structure. Most people who can read a capital structure have never opened a statistical analysis plan. Helix Data Analytics was built at the point where those two skills meet.

The firm conducts independent biostatistical and clinical trial analysis, develops capital markets strategy for clinical-stage companies, and deploys its own capital behind that work. No banking relationships, no sell-side mandates, no conflicts to disclose.

Capabilities

Three capabilities, done at depth.

Helix is a small firm on purpose. It does a narrow set of things for clinical-stage biotechnology companies and does them without an agency layer in between.

Clinical & Biostatistical Analysis

Independent assessment of trial design and results — what a readout actually establishes, and what it does not.

Endpoint selection & trial design
Statistical power, significance & survival modeling
Regulatory pathway assessment

Capital Markets Strategy & Investor Communications

Connecting the science to the shareholder base — translating clinical evidence into a story the market can price, and structuring capital around it.

Valuation & financing structure
Positioning ahead of catalysts
Shareholder base & investor communication strategy

Principal Capital

Helix invests its own capital in the companies it researches. Conviction is expressed with money, not commentary.

Long-horizon, concentrated positions
Micro- and small-cap focus
Aligned with existing shareholders

Method

Three lenses on every company.

Conviction built on one dimension is not conviction. Every company Helix covers is worked through the science, the business, and the statistics — in that order.

The Science

Start with the biology. Mechanism of action, modality, target validation, and the translational rationale — what has to be true for this to work in humans.

The Business

Pressure-test the commercial case. Valuation against cash and enterprise value, addressable market, realistic penetration, competitive positioning, and the financing required to get there.

The Statistics

Interrogate the data itself. Powering, endpoint hierarchy, subgroup credibility, censoring, and what the top-line number conceals as much as what it reveals.

Leadership

The principal.

Richard Doxtator,CFA · MBA

Managing Director

Richard Doxtator founded Helix Data Analytics to work at the intersection of two disciplines that rarely sit at the same desk: reading clinical evidence with statistical rigor, and reading capital markets with institutional discipline.

He holds the CFA charter and an MBA in business economics, and spent years in banking analysis and asset management — including advising high-net-worth clients at a major U.S. wirehouse. That work is the foundation of the firm’s second discipline: understanding how investors actually decide, what moves a shareholder base, and how a clinical-stage company’s story is heard by the people who own it.

His research work centers on micro- and small-cap biotechnology — trial design and survival analysis, regulatory pathways, and the valuation gaps that open when the market cannot read the underlying data.

Contact

Start a conversation.

Helix works with a small number of clinical-stage companies and their boards. Inquiries from management teams, directors, and institutional investors are welcome.

Contact@helixdataanalytics.com

Location

Ponte Vedra, Florida